A variety of underlying mechanisms may be attributed to the role of statins in preventing bone-related disorders.
Rates of incident clinical vertebral fracture, incident nonvertebral fracture, hip fracture, and clinical fractures decreased 6 months after initiation of teriparatide.
Genetic testing may identify individuals with an increased risk for osteoporosis and bone fracture.
Researchers observed a reduction in subsequent nonvertebral fracture rates in patients who initiated osteoporosis treatment.
Investigators determined that reductions in bone mineral density in men with type 1 diabetes occur early in the course of the disease.
A corrected HbA1C factor may improve the ability to predict the risk for fracture by the FRAX algorithm in T2D.
Researchers observed no change in bone mineral density in patients with early and active rheumatoid arthritis who were treated with prednisone or prednisolone vs placebo.
Investigators examined the effect of consuming a Mediterranean-style diet for 1 year on inflammatory response and bone health in the elderly.
Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.
Romosozumab increased spine and hip bone mineral density after 12 months of treatment.
Screening with bone measurement is recommended for women. Younger women are at more risk.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.
The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.
Researchers tested whether semen quality and reproductive function could be a marker of general health in men.
Roux-en Y gastric bypass increased the likelihood of nonvertebral fractures, including hip, wrist, and pelvic fractures.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.
In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.
In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.
Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.
The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.
The USPSTF commissioned a systematic evidence review on vitamin D, calcium, and combined supplementation for the primary prevention of fractures in community-dwelling adults.
Researchers conducted a systematic review of available literature to create a guide for optimal management of patients with type 2 diabetes and osteoporosis.
The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.
Endocrinology Advisor Articles
- Trends in Cardiovascular Deaths for US Adults With and Without Diabetes
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Comparing Efficacies of Second-Line Treatments in Type 2 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency